These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27834341)

  • 21. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Radiosensitization induced by vemurafenib].
    Ducassou A; David I; Delannes M; Chevreau C; Sibaud V
    Cancer Radiother; 2013; 17(4):304-7. PubMed ID: 23810304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 24. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
    Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
    Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma.
    Bhattacharyya A; Cooper A; Hong A; Iland H; McNeil C
    Intern Med J; 2014 Feb; 44(2):207-8. PubMed ID: 24528820
    [No Abstract]   [Full Text] [Related]  

  • 27. BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma.
    Afshar K; David S; Fuehner T; Gottlieb J; Gutzmer R
    JAMA Dermatol; 2016 Feb; 152(2):228-30. PubMed ID: 26502378
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.
    Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT
    J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754
    [No Abstract]   [Full Text] [Related]  

  • 30. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
    Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
    G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
    Trappe R; Budde U; Zimmermann H
    Thromb Haemost; 2012 Oct; 108(4):798-800. PubMed ID: 22918265
    [No Abstract]   [Full Text] [Related]  

  • 32. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
    Dzienis MR; Atkinson VG
    Melanoma Res; 2014 Aug; 24(4):349-53. PubMed ID: 24709889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy.
    Maleka A; Enblad G; Sjörs G; Lindqvist A; Ullenhag GJ
    J Clin Oncol; 2013 Apr; 31(11):e192-3. PubMed ID: 23401457
    [No Abstract]   [Full Text] [Related]  

  • 34. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 36. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
    Dooley AJ; Gupta A; Middleton MR
    Target Oncol; 2016 Aug; 11(4):557-63. PubMed ID: 26857260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
    Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
    Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined inhibition of BRAF and MEK in melanoma patients.
    Infante JR; Swanton C
    Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.